

## TRANSFUSION MEDICINE

# Effect of donor, component, and recipient characteristics on hemoglobin increments following red blood cell transfusion

Nareg H. Roubinian,<sup>1,3</sup> Colleen Plimier,<sup>1</sup> Jennifer P. Woo,<sup>4</sup> Catherine Lee,<sup>1</sup> Roberta Bruhn,<sup>2,3</sup> Vincent X. Liu,<sup>1</sup> Gabriel J. Escobar,<sup>1</sup> Steven H. Kleinman,<sup>5</sup> Darrell J. Triulzi,<sup>6</sup> Edward L. Murphy,<sup>3,2</sup> and Michael P. Busch<sup>2,3</sup>

<sup>1</sup>Kaiser Permanente Northern California Division of Research, Oakland, CA; <sup>2</sup>Vitalant Research Institute, San Francisco, CA; <sup>3</sup>Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA; <sup>4</sup>Department of Pathology and Laboratory Medicine, University of California, Irvine, Irvine, CA; <sup>5</sup>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; and <sup>6</sup>Department of Pathology, University of Pittsburgh, Pittsburgh, PA

## KEY POINTS

- Blood donor, component, and recipient characteristics are significant predictors of hemoglobin increments after RBC transfusion.
- Collectively, these factors account for the variation observed in practice and allow prediction of changes in hemoglobin with transfusion.

**Significant research has focused individually on blood donors, product preparation and storage, and optimal transfusion practice. To better understand the interplay between these factors on measures of red blood cell (RBC) transfusion efficacy, we conducted a linked analysis of blood donor and component data with patients who received single-unit RBC transfusions between 2008 and 2016. Hemoglobin levels before and after RBC transfusions and at 24- and 48-hour intervals after transfusion were analyzed. Generalized estimating equation linear regression models were fit to examine hemoglobin increments after RBC transfusion adjusting for donor and recipient demographic characteristics, collection method, additive solution, gamma irradiation, and storage duration. We linked data on 23 194 transfusion recipients who received one or more single-unit RBC transfusions (n = 38 019 units) to donor demographic and component characteristics. Donor and recipient sex, Rh-D status, collection method, gamma irradiation, recipient age and body mass index, and pretransfusion hemoglobin levels were significant predictors of hemoglobin increments in univariate and multivariable analyses ( $P < .01$ ). For hemoglobin increments 24 hours after transfusion, the coefficient of determination**

**for the generalized estimating equation models was 0.25, with an estimated correlation between actual and predicted values of 0.5. Collectively, blood donor demographic characteristics, collection and processing methods, and recipient characteristics accounted for significant variation in hemoglobin increments related to RBC transfusion. Multivariable modeling allows the prediction of changes in hemoglobin using donor-, component-, and patient-level characteristics. Accounting for these factors will be critical for future analyses of donor and component factors, including genetic polymorphisms, on posttransfusion increments and other patient outcomes. (*Blood*. 2019;134(13):1003-1013)**

## Introduction

The role of blood donor demographic and genetic characteristics, component processing, and recipient factors on transfusion efficacy is an area of high interest in transfusion medicine research.<sup>1,2</sup> Although inherent variability in the blood donor population is known to affect blood component quality, the impact on transfusion recipient outcomes remains unclear.<sup>3-6</sup> In addition, differences in blood collection methods (eg, manual or apheresis), anticoagulants and storage solutions, and leukoreduction result in products with different physiological and biochemical characteristics through storage.<sup>7,8</sup>

The development of linked blood donor–component–recipient databases provides the capacity to interrogate relevant questions in transfusion medicine.<sup>9-11</sup> Donor and component characteristics may affect rates of in vitro hemolysis or the hemoglobin content of a unit of RBC. RBC products from male donors are known to have higher total hemoglobin content than those from their female counterparts; however, rates of storage hemolysis are higher in male donor–derived RBC units and vary with donor age in both sexes.<sup>12,13</sup> Differences in hemolysis may be clinically relevant given the reported (albeit controversial) associations of blood

donor age and sex with adverse outcomes in transfusion recipients.<sup>3,5,6</sup>

Blood collection method, component manufacturing methods, and choice of additive solutions have also been shown to affect characteristics of transfused products and may influence product quality.<sup>14,15</sup> Both gamma irradiation and prolonged storage duration of RBC components have been associated with increased in vitro and in vivo hemolysis.<sup>16-19</sup> In addition, recipient characteristics are relevant to outcomes of RBC transfusion. Circulating blood volumes differ with recipient sex and body mass index (BMI) and play a role in adverse transfusion reactions.<sup>20-22</sup> A transfusion recipient's inflammatory state is also known to be critical in the pathogenesis of transfusion-related acute lung injury and sickle cell disease, and recipient comorbidities have been associated with RBC alloimmunization.<sup>23,24</sup>

The advent of precision medicine seeks to tailor health care delivery to achieve maximum benefit based on an understanding of the factors that contribute to health and disease at individual and population levels.<sup>25</sup> One measure of transfusion efficacy is the hemoglobin increment after transfusion of each packed RBC unit. The common and historical assumption among clinicians is that transfusion of a single RBC unit results in a 1-g/dL increase in hemoglobin levels.<sup>26</sup> However, there are few data examining the relative contribution of donor, component collection and manufacturing, and recipient characteristics on outcomes after transfusion. We sought to quantitatively evaluate the role of these factors on hemoglobin increments related to RBC transfusion and hypothesized that collectively they would account for the significant variation seen in clinical practice.

## Materials and methods

### Study design and setting

This retrospective cohort study was conducted by using electronic health record data from Kaiser Permanente Northern California (KPNC), which serves a population of >4 million patients. All KPNC hospitals and clinics use a common electronic health record (Epic, Verona, WI). The KPNC and University of California, San Francisco, Institutional Review Boards approved this study.

### Blood donor and component characteristics

Information on blood donors, donations, and processing was obtained from databases of the Vitalant Research Institute, which collected blood at multiple blood centers and supplied blood components to 9 of 21 KPNC facilities. All blood products were leukocyte-depleted by prestorage filtration, and all donors were at least 16 years old. Data collected included donor demographic characteristics (age and sex), RBC collection date and method (whole blood or apheresis), and blood component characteristics (ABO/Rh-status, irradiation status, and additive solution) for each unit collected. In a subset of donations from 1 blood center, details regarding donor smoking status and timing of gamma irradiation were included.

### Recipient cohort and characteristics

The study included all adult KPNC inpatients and outpatients who received a single RBC unit during one or more transfusion episodes at 9 medical centers from January 1, 2008, to June 30, 2016. Recipient details included age, sex, and BMI, as well as the

storage duration, transfusion date and time, and product identification numbers of transfused RBCs. We collected hemoglobin levels measured by the clinical laboratory before and after each RBC transfusion event. To assess the role of patient diagnoses, we grouped diagnosis codes from the ninth and 10th revisions of the *International Classification of Diseases* by using Health Care Utilization Project ([www.ahrq.gov/data/hcup](http://www.ahrq.gov/data/hcup)) Clinical Classifications Software categories.

### Outcomes

The primary outcome was the recipient's hemoglobin increment after a single RBC unit transfusion. Changes in hemoglobin levels were calculated as the difference in the proximate pretransfusion hemoglobin levels and posttransfusion hemoglobin levels at time intervals after transfusion. Transfusions were excluded from analyses if there were no pretransfusion or posttransfusion hemoglobin levels in the specific time periods or if the patient received multiple RBC transfusions during a single transfusion episode.

Pretransfusion hemoglobin levels were defined as the proximate hemoglobin level before transfusion; for this analysis, the time from determination of the pretransfusion hemoglobin level to the blood transfusion was limited to  $\leq 18$  hours. Initial hemoglobin levels within 18 hours after transfusion ( $Hb_{post}$ ) and for 24 hours ( $Hb_{post24}$ ) and 48 hours ( $Hb_{post48}$ ) after the transfusion periods were assessed.  $Hb_{post24}$  was defined as the posttransfusion hemoglobin level closest to 24 hours after transfusion, within an 18- to 36-hour posttransfusion window, with no intervening transfusion.  $Hb_{post48}$  was the posttransfusion hemoglobin level closest to 48 hours after transfusion, within a 36- to 60-hour window, with no intervening transfusion.

### Statistical Analysis

Donor, component, and recipient characteristics were linked by using product identification numbers of recipients' transfused RBCs. We then quantitatively evaluated associations between these factors and hemoglobin increments for each transfused RBC unit. We first examined univariate associations between hemoglobin increments and donor sex, age, and Rh status, as well as recipient characteristics, including age, sex, BMI, and pretransfusion hemoglobin levels. Given conflicting findings regarding bleeding risk related to blood type, we analyzed changes in hemoglobin for blood group O vs non-O.<sup>27</sup> We also examined hemoglobin increments based on blood collection method (whole blood or apheresis-derived), gamma irradiation, and RBC storage duration. Given the potential for selection bias due to infrequently used storage solutions, we focused analyses on additive solutions 1 and 3 (AS-1 and AS-3, respectively). To account for the possibility of indication bias with receipt of gamma irradiated RBCs, hemoglobin increments were additionally evaluated in patients whose primary diagnoses was related to neoplasm (eg, leukemia, lymphoma, solid tumor, receipt of chemotherapy).

We then examined multivariable associations between all exposures and hemoglobin increments simultaneously. Generalized estimating equations (GEE) were used to account for correlated transfusion events in a given recipient. Models were fit to examine hemoglobin increments after RBC transfusion, adjusting for the aforementioned donor, component, and recipient characteristics. Interactions between individual factors




Figure 1. Study flow diagram. Hb, hemoglobin.

were examined to detect the presence of effect modification. Intervals from the time of laboratory testing (pretransfusion and posttransfusion hemoglobin levels) in relation to transfusion time, as well as the year of transfusion, were accounted for. Separate models were fit to examine hemoglobin increments initially after transfusion and for 24- and 48-hour periods after transfusion. We selected the correlation structure with the best model fit based on the quasi-likelihood under the independence model criterion (QIC). As secondary analyses, we fit the aforementioned models for the transfusion episodes available in all 3 posttransfusion time periods (initial, 24-hour, and 48-hour) as well as for inpatient vs outpatient transfusion episodes.

Data are presented as counts and percentages, means with standard deviations (SDs), or medians and interquartile ranges (IQRs). Accordingly,  $\chi^2$  tests for equal proportion, Student *t* tests, or Wilcoxon rank sum tests were used to test differences. Regression results were reported as coefficients with 95% confidence intervals representing the mean hemoglobin increment after RBC transfusion for that variable. To assess model fit, we calculated the coefficient of determination ( $R^2$ ) for GEE models and assessed calibration by using plots of predicted vs actual

hemoglobin increments and corresponding correlation.<sup>28</sup> Two-sided *P* values  $<.05$  were considered to be statistically significant. Statistical analyses were performed by using Stata version 14.1 (StataCorp, College Station, TX), R version 3.4.1 (R Foundation for Statistical Computing, Vienna, Austria), and SAS version 9.4 (SAS Institute, Inc., Cary, NC).

## Results

We identified 139 433 patients who received 708 256 RBC transfusions at KPNC facilities from 2008 to 2016 (Figure 1). Blood donor demographic data were available for 9 of 21 medical centers and were linked to 63 162 recipients who received 268 017 RBC transfusions. Among the linked donor–recipient transfusions, hemoglobin data before and after transfusion were available for 151 060 transfusion episodes, and 55 312 of these 151 060 transfusion episodes represented a single RBC unit transfusion. Single-unit transfusion episodes were further limited to those with hemoglobin determinations within 18 hours before transfusion and 60 hours after transfusion, resulting in 38 019 informative transfusion episodes occurring in inpatient ( $n = 29\,045$ ) and outpatient ( $n = 8\,974$ ) settings.

**Table 1. Donor, component, and recipient characteristics**

No. of informative transfusion episodes	38 019
<b>Blood donor characteristics</b>	
Male sex, %	57.3
Age, median (IQR), y	47 (29-58)
(+) Rh status, %	81.7
ABO status, %	
A	36.9
B	1.9
AB	12.3
O	48.9
<b>Blood component characteristics</b>	
Gamma irradiated, %	6.5
RBC storage duration, median (IQR), d	26 (20-32)
Apheresis-derived, %	21.4
Storage solution, %	
AS-1	23.9
AS-3	70.6
CPDA	4.2
AS-5	1.3
<b>Transfusion recipient characteristics</b>	
Male sex, %	49.9
Age, median (IQR), y	72 (61-81)
BMI, median (IQR), kg/m <sup>2</sup>	26.3 (23.0-31.0)
(+) Rh status, %	87.9
ABO status, %	
A	36.8
B	3.8
AB	13.7
O	45.7
Pretransfusion Hb, mean SD, g/dL	8.00 (0.88)
Posttransfusion Hb, mean SD, g/dL	9.04 (1.15)
Time between pretransfusion Hb and transfusion, median (IQR), h	5.0 (2.6-8.5)
Time between transfusion and posttransfusion Hb, median (IQR), h	5.8 (3.7-11.4)

CPDA, citrate-phosphate-dextrose-adenine.

Hemoglobin levels within the initial posttransfusion, 24-hour, and 48-hour periods occurred without additional interval transfusions in 38 019, 27 384, and 17 038 episodes, respectively.

For the 38 019 informative transfusion episodes, the median blood donor age was 47 years (IQR, 29-58 years), and 57.3% of transfused RBC units were from male donors (Table 1). Median transfusion recipient age was 72 years (IQR, 61-81 years), and 49.9% were male. Overall, 21.4% of all transfused RBC units were derived from apheresis collections, 70.6% were stored in AS-3, 6.5% underwent gamma irradiation, and the median storage duration was 26 days (IQR, 20-32 days). These characteristics were similar for recipients for whom 24- and 48-hour hemoglobin levels were available (supplemental Table 1, available on the *Blood* Web site). Recipient demographic characteristics were also similar for episodes in which donor data were not available and for recipients of multiple unit RBC transfusion episodes not included in the analysis (supplemental Table 2).

The mean  $\pm$  SD pretransfusion hemoglobin level was 8.00  $\pm$  0.88 g/dL and was measured 5 hours (IQR, 2.6-8.5 hours) before

transfusion. The initial posttransfusion hemoglobin level was measured 5.8 hours (IQR, 3.7-11.4 hours) after transfusion, and the median times from transfusion to Hb<sub>post24</sub> and Hb<sub>post48</sub> were 23.7 hours (IQR, 20.4-28.9 hours) and 43.7 hours (IQR, 40.0-50.5 hours), respectively.

For the initial posttransfusion period (Table 2), the hemoglobin increment was 1.04  $\pm$  0.89 g/dL. Larger hemoglobin increments were seen in recipients of RBC units from male donors (mean  $\pm$  SD, 1.08  $\pm$  0.87 g/dL) compared with female donors (1.01  $\pm$  0.89 g/dL;  $P < .001$ ). Hemoglobin increments were also larger in recipients of whole blood–derived RBC units (1.07  $\pm$  0.88 g/dL) compared with apheresis-derived RBC units (0.97  $\pm$  0.87 g/dL;  $P < .001$ ). Similar findings were observed for Hb<sub>post24</sub> and Hb<sub>post48</sub> posttransfusion periods (supplemental Table 3). Hemoglobin increments were reduced for transfusion of RBC units from donors aged  $>70$  years compared with all other donors at 24- and 48-hour posttransfusion periods ( $P = .017$  and  $.015$ , respectively) (supplemental Table 4). Positive donor or recipient Rh-D status was associated with larger hemoglobin increments compared with negative Rh-D status ( $P < .001$ ).

There were no significant differences in hemoglobin increments related to RBC storage duration in univariable comparisons (Table 2; supplemental Table 3). Recipients of irradiated RBC units vs unirradiated RBC units had smaller hemoglobin increments (0.98 vs 1.06;  $P < .001$ ), and these differences did not vary according to RBC storage duration or time from gamma irradiation (supplemental Tables 5 and 6). Hemoglobin increments were reduced for recipients of irradiated units with and without oncologic diagnoses (Table 3).

Female transfusion recipients and patients with lower BMI had larger hemoglobin increments compared with male and overweight or obese individuals (Table 2). Hemoglobin increments were inversely proportional to hemoglobin levels, with larger increments associated with progressive degrees of pretransfusion anemia. The effects of individual donor, component, and recipient characteristics seemed to be additive, with the lowest increments observed in male recipients of irradiated or apheresis-derived units from female donors (Tables 4 and 5). Lastly, hemoglobin increments did not vary significantly according to donor smoking status (supplemental Table 7).

Table 6 shows regression estimates from the multivariate model for the initial posttransfusion period, accounting for correlated transfusion events. Regression coefficients estimate the mean hemoglobin increment after transfusion for each level change (for categorical variables) or unit increase (for continuous variables) of each predictor. The aforementioned univariate findings of donor, component, and recipient characteristics remained significantly associated with changes in hemoglobin levels for the initial posttransfusion period as well as within the 24- and 48-hour windows (supplemental Table 8). In addition, hemoglobin increments were smaller for components stored in AS-3 vs AS-1 ( $-0.05$  g/dL;  $P = .01$ ). Donor age and RBC storage duration were not significant predictors initially after transfusion, but donor age  $>70$  years and storage duration  $>35$  days exhibited small but statistically significant associations with decreased hemoglobin increments at 24- and 48-hour periods after transfusion (all,  $P < .05$ ).

**Table 2. Univariate changes in Hb levels after transfusion (N = 38 019)**

Variable	Hb increment, g/dL	P*
Overall change in Hb level	1.04 ± 0.89	
<b>Blood donor characteristic</b>		
Donor sex		<.001
Male	1.08 ± 0.87	
Female	1.01 ± 0.89	
Donor age		.43
<20 y	1.05 ± 0.89	
20-44 y	1.04 ± 0.89	
45-70 y	1.05 ± 0.88	
>70 y	1.02 ± 0.84	
Donor Rh status		<.001
Negative	1.01 ± 0.89	
Positive	1.06 ± 0.87	
Donor ABO blood group†		.14
O	1.04 ± 0.90	
Non-O	1.06 ± 0.89	
<b>Blood component characteristic</b>		
Collection method		<.001
Apheresis-derived	0.97 ± 0.87	
Whole blood	1.07 ± 0.88	
Storage duration‡		.09
1-21 d	1.04 ± 0.89	
22-28 d	1.05 ± 0.90	
29-35 d	1.06 ± 0.86	
36-42 d	1.05 ± 0.84	
RBC solution, %		.80
AS-1	1.04 ± 0.89	
AS-3	1.05 ± 0.87	
Gamma irradiation		<.001
Yes	0.98 ± 0.81	
No	1.06 ± 0.88	
<b>Transfusion recipient characteristic</b>		
Recipient sex		<.0001
Male	0.91 ± 0.83	
Female	1.19 ± 0.91	
Recipient age		<.0001
18-55 y	0.96 ± 0.92	
56-69 y	0.98 ± 0.87	
70-80 y	1.05 ± 0.86	
>80 y	1.16 ± 0.87	
Recipient BMI		<.0001
Underweight	1.44 ± 0.96	
Normal	1.16 ± 0.92	
Overweight	1.03 ± 0.86	
Obese	0.89 ± 0.80	
Recipient Rh status		<.0001
Negative	1.00 ± 0.88	
Positive	1.06 ± 0.88	
Recipient ABO blood group†		
O	1.04 ± 0.89	
Non-O	1.05 ± 0.86	

**Table 2. (continued)**

Variable	Hb increment, g/dL	P*
Pretransfusion Hb level		<.0001
<7 g/dL	1.26 ± 0.95	
7-8 g/dL	1.11 ± 0.82	
>8 g/dL	0.96 ± 0.89	

\*P values correspond to Student t tests.

†Non-O blood group includes A, B, and AB blood types.

‡Increments for other storage solutions included in supplemental Table 3.

The estimated coefficients of determination ( $R^2$ ) for the GEE multivariate models were 0.18, 0.25, and 0.28 for the initial, 24-hour, and 48-hour posttransfusion increments, respectively.<sup>28</sup> Estimated correlations between the predicted and actual hemoglobin increments were 0.43, 0.50, and 0.53 for the initial, 24-hour, and 48-hour increments. In the secondary analyses restricted to the 17 038 episodes available for all 3 posttransfusion time periods and between inpatient and outpatient transfusion episodes, results were comparable to the main analyses (supplemental Tables 9 and 10). Regression coefficients from a simplified GEE model were used to estimate the initial post-transfusion hemoglobin increment representing the spectrum of combinations of donor, component, and recipient characteristics for a pretransfusion hemoglobin level of 7 g/dL (Table 7).

## Discussion

In this retrospective cohort study, the effects of blood donor, component, and recipient factors on hemoglobin increments after RBC transfusion were evaluated as a measure of transfusion efficacy. Overall, transfusion of a single unit of RBC resulted in an expected increase of 1 g/dL. However, combinations of donor, component, and recipient characteristics were responsible for a substantial proportion of the variation observed clinically. In addition to affirming clinically plausible recipient factors, this study provides relevant clinical practice data identifying measurable differences in hemoglobin increments related to donor sex, collection method, storage solution, and gamma irradiation of RBC. Collectively, these donor, component, and recipient factors could be used to estimate expected changes in hemoglobin levels after RBC transfusion.

Although not previously shown, findings of larger hemoglobin increments from transfusion of male-derived RBC units are not unexpected, given the higher RBC mass and content in 500-mL whole blood collections from male donors. However, in vitro studies have shown that RBCs from male donors and those exposed to testosterone exhibit increased susceptibility to spontaneous and stress-induced hemolysis after storage compared with female RBCs or exposure to female hormones.<sup>13</sup> Detection of in vivo hemolysis of male-derived donor RBCs (as reflected by hemoglobin increment) may be masked by the higher hemoglobin content of these collections. RBC recovery and survival studies (with chromium-51 or biotin labeling) would obviate the need for future investigations to normalize for the hemoglobin dose of each RBC unit when assessing the impact of in vitro (during storage) and in vivo hemolysis.<sup>29,30</sup>

**Table 3. Hb increments in relation to oncologic Dx and gamma irradiation status**

Variable	Initial Hb increment, g/dL*		24-h Hb increment, g/dL*	
	Nononcologic Dx (n = 34 516)	Oncologic Dx (n = 3503)	Nononcologic Dx (n = 24 697)	Oncologic Dx (n = 2687)
<b>Unirradiated</b>				
Pre-Tx Hb	8.03 (0.87)	7.96 (0.89)	8.05 (0.82)	7.96 (0.80)
Post-Tx Hb	9.08 (1.14)	9.01 (1.24)	9.09 (1.18)	8.99 (1.14)
Hb increment	1.06 (0.88)	1.06 (0.96)	1.04 (0.90)	1.03 (0.92)
<b>Irradiated</b>				
Pre-Tx Hb	7.78 (0.84)	7.64 (0.73)	7.77 (0.84)	7.62 (0.73)
Post-Tx Hb	8.74 (1.13)	8.53 (1.09)	8.75 (1.16)	8.44 (0.99)
Hb increment	1.00 (0.81)	0.92 (0.87)	0.98 (0.90)	0.82 (0.82)

All presented data are mean ± SD.

Dx, diagnosis; Tx, transfusion.

\*Pretransfusion Hb levels within 18 hours of Tx, and Hb increments within 18-hour period after Tx for the initial period and between the 18- and 36-hour period after Tx for 24-hour increment. Tx recipients of gamma irradiated RBCs compared with unirradiated RBCs had smaller Hb increments in patients with and without an oncologic Dx. All *P* values <.001 by Student *t* tests.

In parallel with donor sex, donor age is a characteristic that may have implications for transfusion outcomes.<sup>3,31</sup> We found smaller hemoglobin increments for the RBC units transfused from the oldest group of donors. In older individuals, an inadequate rise in erythropoietin to compensate for aging marrow cells or loss of hematopoietic stem cell reserve may affect the red cell.<sup>32-34</sup> In addition, frequent blood donation has been associated with iron deficiency or iron-deficient erythropoiesis in older blood donors.<sup>35</sup> Iron status in donors varies with age according to sex due to menstruation and pregnancy, and donor iron deficiency has been shown to affect posttransfusion recovery of RBCs in murine studies.<sup>36</sup> Although measurable, differences related to donor age did not seem to have a clinically relevant effect on hemoglobin increments. Additional studies are needed to examine the relation between donor age, donation frequency, and storage duration on additional recipient outcomes.

Blood component manufacturing methods have been shown to influence in vitro characteristics of RBC products during storage, including hemoglobin content, biochemical properties, and rates of in vitro storage hemolysis.<sup>37-39</sup> Biochemical and immunomodulatory differences have been observed between units collected from whole blood and apheresis.<sup>8,15</sup> For example, mitochondrial DNA release and extracellular vesicle damage-associated molecular patterns were increased in apheresis compared with whole blood-derived collections.<sup>14</sup> We identified smaller hemoglobin increments in apheresis-derived units compared with whole blood-derived RBC collections. Higher RBC content in whole blood collections likely explains the larger hemoglobin increments; however, further investigation is needed to better understand these differences and other outcomes.

In the current cohort, gamma irradiation was associated with smaller hemoglobin increments compared with nonirradiated RBC units. Irradiation has been shown to increase potassium and free hemoglobin in the supernatant of RBC units through disruption of membrane integrity.<sup>16,40</sup> Irradiated RBC units have also been shown to result in decreased recovery of RBCs after transfusion, particularly after longer durations of storage.<sup>41,42</sup> In addition, a recent study found that in vitro storage of irradiated RBC units from female subjects had lower levels of hemolysis

compared with male-derived RBCs.<sup>43</sup> Based on our understanding of irradiation on in vitro RBC viability, it is relevant to show that gamma irradiation negatively affected hemoglobin increments. Accounting for potential selection bias in the receipt of an irradiated unit, we confirmed this finding in recipients with and without oncologic diagnoses. Interestingly, the effect of irradiation did not seem to be associated with the storage duration of the RBC product or with donor sex. Additional investigations are needed to correlate hemoglobin increments for irradiated units with in vivo measures of RBC hemolysis and other recipient outcomes.

The notion of the “red cell storage lesion” derives from a number of in vitro changes that occur during RBC storage, which may adversely affect RBC quality and function.<sup>17</sup> The clinical significance of RBC storage has been studied in a series of randomized controlled trials (RCTs), which have not shown differences in morbidity and mortality outcomes when comparing fresh and stored RBCs.<sup>44-48</sup> The majority of these RCTs have not been powered to study the effect of RBCs stored beyond 35 days; in addition, these clinical trials did not examine associations of RBC storage on other measures of component efficacy.<sup>49,50</sup> Similar to a recent study, we found that RBC storage duration beyond 35 days was associated with reduced hemoglobin increments after transfusion.<sup>51</sup> This finding also parallels that of a prospective study of storage duration of autologous RBC units conducted in healthy volunteers that additionally detected increases in non-transferrin-bound iron and extravascular measures of hemolysis at the end of storage.<sup>18</sup> Pending further RCTs, mechanistic clinical investigations and well-conducted observational studies provide us with the best evidence regarding the effectiveness and safety profile of 35- to 42-day-old RBC products.<sup>19,52</sup>

Reduced hemoglobin increments after selected RBC transfusion may reflect poor storage of blood components from specific donors with genetic polymorphisms.<sup>53</sup> Genetic mutations associated with hemoglobinopathies, enzymopathies, and membranopathies have been postulated to affect RBC recovery during storage and after transfusion.<sup>54</sup> Recently, the REDS-III RBC-Omics study found that RBCs from donors with Asian and

**Table 4. Hb increments for donor and recipient sex and gamma irradiation status\***

Variable	Male blood donor		Female blood donor	
	Unirradiated (n = 20 275)	Irradiated (n = 1505)	Unirradiated (n = 15 267)	Irradiated (n = 972)
<b>Female recipient</b>				
Pre-Tx Hb	8.02 (0.88)	7.80 (0.86)	8.00 (0.90)	7.79 (0.84)
Post-Tx Hb	9.25 (1.18)	8.99 (1.20)	9.14 (1.17)	8.88 (1.18)
Hb increment	1.23 (0.93)	1.18 (0.96)	1.14 (0.89)	1.08 (0.84)
<b>Male recipient</b>				
Pre-Tx Hb	8.03 (0.86)	7.76 (0.83)	8.04 (0.88)	7.75 (0.85)
Post-Tx Hb	8.97 (1.11)	8.64 (1.08)	8.92 (1.13)	8.50 (1.10)
Hb increment	0.93 (0.83)	0.88 (0.79)	0.88 (0.84)	0.74 (0.77)

All presented data are mean ± SD. Pretransfusion Hb level within 18 hours of transfusion (Tx) and Hb increments within 18-hour period after Tx. Hb values are given in grams per deciliter. \*P < .001 for mean trend in Hb increments across donor, component, and recipient status.

African American ethnic backgrounds were associated with increased susceptibility to hemolysis after prolonged storage.<sup>12</sup> Although the role of individual genetic polymorphisms may be small, combinations of heritable variants in relevant RBC genes in donors may substantially modulate in vitro hemolysis during storage and in vivo efficacy of RBC transfusions.<sup>55</sup> Genome-wide association and metabolomic studies are in progress to further clarify these findings, including analysis of the outcomes of RBC transfusion episodes from the donors we present here.<sup>56,57</sup> Also planned are mechanistic studies to determine if larger hemoglobin increments in Rh-D–positive donors and recipients have a genetic or metabolomic basis or if this finding represents residual confounding.<sup>58</sup> Accounting for donor, component, and recipient factors documented in the current analysis will be critical to future studies examining the contribution of donor genetic polymorphisms on in vivo hemolysis and posttransfusion RBC recovery.

Today, transfusion services are increasingly adopting multidisciplinary patient blood management measures to provide fewer and more effective transfusions to achieve clinical outcomes, including adequate hemostasis. The role of individual recipient factors on hemoglobin increments after RBC transfusion has previously been described.<sup>59-61</sup> Increased increments for recipients with lower pretransfusion hemoglobin levels may reflect the relatively larger effect of the same RBC dose (~89 g of hemoglobin per transfused unit) in patients with acutely reduced

red cell mass or circulating blood volumes.<sup>62-64</sup> In this study, the difference in hemoglobin increments in sex-mismatched vs same sex donors and recipients was also striking. Male recipients of female-derived RBCs had significantly smaller increments than female recipients of male-derived units. Future studies should examine the role of hemoglobin increments and need for additional transfusion exposure when evaluating adverse outcomes associated with donor and transfusion recipient sex-mismatch. Furthermore, the variability in hemoglobin increments due to this and other factors (eg, component manufacturing methods) should be considered in the conduct of multicenter clinical trials of RBC transfusions, which frequently use multiple blood suppliers that collect, process, and store components differently.

In the current study, individual donor, component, and recipient characteristics played a small role in hemoglobin increments. However, collectively, they accounted for the significant variation observed in clinical practice and the substantial correlation between actual and predicted outcomes in regression model performance. Dramatically different increments after transfusion for the same pretransfusion hemoglobin level could affect clinical decision-making. For example, a suboptimal hemoglobin increment (eg, <0.8 g/dL) after transfusion may raise the question of ongoing bleeding or hemolysis, whereas a larger-than-expected increment may be falsely reassuring (Table 7). Prediction of hemoglobin increments using donor, component,

**Table 5. Hb increments for donor and recipient sex and blood collection method\***

Variable	Whole blood collection		Apheresis collection	
	Male donor (n = 14 875)	Female donor (n = 15 025)	Male donor (n = 6905)	Female donor (n = 1214)
<b>Female recipient</b>				
Pre-Tx Hb	7.97 (0.88)	7.98 (0.89)	8.04 (0.88)	7.92 (0.88)
Post-Tx Hb	9.25 (1.18)	9.13 (1.16)	9.15 (1.15)	8.96 (1.12)
Hb increment	1.29 (0.93)	1.14 (0.89)	1.10 (0.90)	1.04 (0.82)
<b>Male recipient</b>				
Pre-Tx Hb	7.98 (0.86)	8.00 (0.88)	8.05 (0.86)	8.09 (0.88)
Post-Tx Hb	8.96 (1.11)	8.88 (1.13)	8.90 (1.10)	8.88 (1.18)
Hb increment	0.97 (0.82)	0.88 (0.83)	0.85 (0.82)	0.79 (0.86)

All presented data are mean ± SD. Pretransfusion Hb level within 18 hours of transfusion (Tx) and Hb increments within 18-hour period after Tx. Hb values are given in grams per deciliter. \*P < .001 for mean trend in Hb increments across donor, component, and recipient status.

**Table 6. Regression estimates for hemoglobin increment in the initial posttransfusion period (n = 38 019)**

Characteristic	Change in hemoglobin (95% CI)	P
Male donor	0.10 (0.08 to 0.12)	<.01
<b>Donor age (reference, &lt;20 y)</b>		
20-45	0.00 (-0.03 to 0.03)	.95
45-70	0.00 (-0.02 to 0.03)	.81
>70	-0.03 (-0.08 to 0.01)	.14
Donor Rh-positive status	0.00 (-0.04 to 0.03)	.86
<b>Donor ABO status (ref: non-O)</b>		
Blood type O	-0.01 (-0.07 to 0.04)	.65
Whole blood collection	0.16 (0.13 to 0.18)	<.001
<b>Storage duration (ref: 1-21 d)</b>		
22-28	-0.00 (-0.03 to 0.03)	.41
29-35	-0.00 (-0.02 to 0.01)	.73
36-42	-0.02 (-0.04 to 0.01)	.27
<b>RBC additive solution (reference, AS-1)*</b>		
AS-3	-0.07 (-0.12 to -0.02)	.01
Gamma irradiation	-0.06 (-0.10 to -0.02)	.002
Female recipient	0.28 (0.26 to 0.29)	<.001
Recipient age†	0.04 (0.04 to 0.05)	<.001
Recipient BMI	-0.02 (-0.02 to -0.02)	<.001
Recipient Rh-positive status	0.06 (0.01 to 0.10)	.01
<b>Recipient ABO status (reference, non-O)</b>		
Blood type O	0.01 (-0.06 to 0.08)	.87
Pre-transfusion Hb level	-0.18 (-0.20 to -0.17)	<.001
Hours between pre-Tx measurement and Tx	0.01 (0.01 to 0.01)	<.001
Hours between Tx and post-Tx measurement	0.01 (0.01 to 0.01)	<.001
Tx year	-0.02 (-0.02 to -0.01)	<.001

Pretransfusion Hb level within 18 hours of transfusion (Tx) and change in Hb within 18-hour period after Tx. Hb changes are given in grams per deciliter. CI, confidence interval.

\*Regression estimates for other storage solutions included in appendix tables.

†Coefficient for recipient age corresponds to change in mean outcome associated with 10-year increase.

and recipient data could also be used to optimize transfusion efficacy, especially in chronically transfused patients or resource-limited settings.

Results from research studies examining how biological factors in blood donors and component modifications contribute to the quality of RBC units will likely shape the way patients undergo transfusions in the future. Linked donor–component–recipient databases have the potential to validate laboratory or clinical trial findings. For example, differences in hemoglobin increments identified for RBCs stored in AS-3 correlated with in vitro and metabolomic findings, and they complement results of laboratory investigations of blood donor tobacco use on recipient outcomes.<sup>65,66</sup> Given their sample size and longitudinal nature, linked databases may also be beneficial in providing safety and efficacy data for novel RBC products, processing, additive solutions, and pathogen reduction.<sup>67</sup>

The principal strength of the current study is the large linked donor–component–recipient cohort, which includes granular laboratory and clinical data as well as multivariate analysis to account for interactions and correlated events. Limitations of this study include analysis of recipients who received single-unit RBC transfusions in which the exact timing of hemoglobin levels could not be standardized. However, the overall strength of association of individual blood donor, component, and recipient factors did not vary significantly based on the timing of hemoglobin levels after transfusion. Future analyses accounting for volumes of IV fluids and other blood components concomitantly transfused with RBC units (which are more likely to occur with multiunit RBC episodes than with single-unit transfusions) are needed to assess for possible selection bias and show the generalizability of our findings. Studies focused on platelet and plasma transfusion could be valuable, as donor characteristics have not been well delineated for these products. The source of



**Table 7. Predicted Hb increment after RBC transfusion for individual donor, component, and recipient factors for Hb level of 7 g/dL**

Female donor (0)	Male donor (+0.1)
Donor/recipient Rh-D negative (-0.06)	Donor/recipient Rh-D positive (0)
Apheresis collection (0)	Whole blood collection (+0.16)
Irradiated unit (-0.08)	Unirradiated unit (0)
AS-3 (-0.06)	AS-1 (0)
60-year-old male recipient (0)	85-year-old female recipient (+0.4)
BMI - 30 (-0.5)	BMI - 18 (-0.3)
Cumulative Hb increment: 0.59 g/dL	Cumulative Hb increment: 1.65 g/dL

Simplified Model for Mean HEMOGLOBIN INCREMENT<sub>ij</sub> = 2.41 + 0.1(MALE DONOR<sub>ij</sub>) - .06(DONOR/RECIPIENT RH NEGATIVE<sub>ij</sub>) + 0.16(WHOLE BLOOD<sub>ij</sub>) + -0.06(SOLUTION AS 3<sub>ij</sub>) + -.08(UNIT GAMMA IRRADIATED<sub>ij</sub>) + -0.28(MALE RECIPIENT<sub>ij</sub>) + 0.005(RECIPIENT AGE<sub>ij</sub>) + -.017(RECIPIENT BMI<sub>ij</sub>) + -0.16(PRE-TRANSFUSION HB LEVEL<sub>ij</sub>)

blood could be another relevant factor, as blood products transfused in this study were derived from a single blood supplier. In addition, details regarding blood-processing protocols and apheresis instruments were not available or standardized in our analysis. We are in the process of linking blood donor and component data, including details on collection and processing from other blood suppliers, to examine the role of different RBC manufacturing methods in our transfused recipient cohort. Subsequent analyses will need to account for donation frequency and other donor and component characteristics in adults but also focus on neonatal and pediatric populations.<sup>68</sup> We chose hemoglobin increment as a measure of transfusion efficacy because hemoglobin levels frequently serve as the primary parameter in clinical decision-making for RBC transfusion.<sup>69-71</sup> However, future studies should examine other physiological biomarkers or outcomes to assess transfusion effectiveness and safety.<sup>44</sup>

In conclusion, we describe the association of blood donor characteristics, collection and modification methods, and recipient factors on hemoglobin increments related to RBC transfusion. Multivariate regression analysis revealed that individual donor, component, and recipient characteristics are significant in hemoglobin increments. Collectively, these factors account for much of the variation observed clinically and may have utility in predicting changes in hemoglobin with transfusion. Our findings support the ongoing need for large-scale evaluation of blood donor and component characteristics on recipient outcomes utilizing linked databases to further understand the risks and benefits of RBC transfusion.

## Acknowledgments

The authors acknowledge Jason Lee and the other members of the KPNC Blood Management Advisory Group for facilitating access to the blood bank data used in the study.

## REFERENCES

- Ning S, Heddle NM, Acker JP. Exploring donor and product factors and their impact on red cell post-transfusion outcomes. *Transfus Med Rev*. 2018;32(1):28-35.
- Kanias T, Gladwin MT. Nitric oxide, hemolysis, and the red blood cell storage lesion: interactions between transfusion, donor, and recipient. *Transfusion*. 2012;52(7):1388-1392.
- Chassé M, Timmouth A, English SW, et al. Association of blood donor age and sex with recipient survival after red blood cell transfusion. *JAMA Intern Med*. 2016;176(9):1307-1314.
- Vasan SK, Chiesa F, Rostgaard K, et al. Lack of association between blood donor age and survival of transfused patients. *Blood*. 2016;127(5):658-661.
- Heddle NM, Cook RJ, Liu Y, et al. The association between blood donor sex and age and transfusion recipient mortality: an exploratory analysis. *Transfusion*. 2019;59(2):482-491.

This study was funded by the National Institutes of Health, National Heart, Lung, and Blood Institute (R01HL126130).

## Authorship

Contribution: N.H.R. had full access to the data in the study and takes responsibility for its integrity and the accuracy of the presented analyses; N.H.R., R.B., M.P.B., C.P., and G.J.E. were responsible for acquisition of data; C.P., C.L., and N.H.R. were responsible for the statistical analyses; M.P.B. and G.J.E. supplied administrative, technical, or material support; and all authors were responsible for study concept and design, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: N.H.R., 0000-0002-1063-6155; C.L., 0000-0003-0008-9052; R.B., 0000-0002-5898-8168; G.J.E., 0000-0003-2540-3327.

Correspondence: Nareg H. Roubinian, Kaiser Permanente Division of Research, 2000 Broadway, Oakland, CA 94612; e-mail: nareg.h.roubinian@kp.org.

## Footnotes

Submitted 25 March 2019; accepted 17 July 2019. Prepublished online as *Blood* First Edition paper, 26 July 2019; DOI 10.1182/blood.2019000773.

The online version of this article contains a data supplement.

There is a *Blood* Commentary on this article in this issue.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

6. Edgren G, Murphy EL, Brambilla DJ, et al; NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) Group. Association of blood donor sex and prior pregnancy with mortality among red blood cell transfusion recipients. *JAMA*. 2019; 321(22):2183-2192.
7. Acker JP, Marks DC, Sheffield WP. Quality assessment of established and emerging blood components for transfusion. *J Blood Transfus*. 2016;2016:4860284.
8. Almizraq RJ, Norris PJ, Inglis H, et al. Blood manufacturing methods affect red blood cell product characteristics and immunomodulatory activity. *Blood Adv*. 2018;2(18): 2296-2306.
9. Kleinman S, Busch MP, Murphy EL, Shan H, Ness P, Glynn SA; National Heart, Lung, and Blood Institute Recipient Epidemiology and Donor Evaluation Study (REDS-III). The National Heart, Lung, and Blood Institute Recipient Epidemiology and Donor Evaluation Study (REDS-III): a research program striving to improve blood donor and transfusion recipient outcomes. *Transfusion*. 2014;54(3 pt 2):942-955.
10. Kleinman S, Glynn SA. Database research in transfusion medicine: the power of large numbers. *Transfusion*. 2015;55(7):1591-1595.
11. Edgren G, Rostgaard K, Vasan SK, et al. The new Scandinavian Donations and Transfusions database (SCANDAT2): a blood safety resource with added versatility. *Transfusion*. 2015;55(7):1600-1606.
12. Kanas T, Lanteri MC, Page GP, et al. Ethnicity, sex, and age are determinants of red blood cell storage and stress hemolysis: results of the REDS-III RBC-Omics study. *Blood Adv*. 2017; 1(15):1132-1141.
13. Kanas T, Sinchar D, Osei-Hwedieh D, et al. Testosterone-dependent sex differences in red blood cell hemolysis in storage, stress, and disease. *Transfusion*. 2016;56(10):2571-2583.
14. Bakkour S, Acker JP, Chafets DM, et al. Manufacturing method affects mitochondrial DNA release and extracellular vesicle composition in stored red blood cells. *Vox Sang*. 2016;111(1):22-32.
15. Hansen AL, Kurach JD, Turner TR, et al. The effect of processing method on the in vitro characteristics of red blood cell products. *Vox Sang*. 2015;108(4):350-358.
16. Harm SK, Raval JS, Cramer J, Waters JH, Yazer MH. Haemolysis and sublethal injury of RBCs after routine blood bank manipulations. *Transfus Med*. 2012;22(3):181-185.
17. Antonelou MH, Seghatchian J. Insights into red blood cell storage lesion: toward a new appreciation. *Transfus Apheresis Sci*. 2016; 55(3):292-301.
18. Hod EA, Brittenham GM, Billote GB, et al. Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron. *Blood*. 2011;118(25):6675-6682.
19. Rapido F, Brittenham GM, Bandyopadhyay S, et al. Prolonged red cell storage before transfusion increases extravascular hemolysis. *J Clin Invest*. 2017;127(1):375-382.
20. Murphy EL, Kwaan N, Looney MR, et al; TRALI Study Group. Risk factors and outcomes in transfusion-associated circulatory overload. *Am J Med*. 2013;126(4):357.e29-357.e38.
21. Roubinian NH, Hendrickson JE, Triulzi DJ, et al; National Heart, Lung, and Blood Institute (NHLBI) Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Contemporary risk factors and outcomes of transfusion-associated circulatory overload. *Crit Care Med*. 2018;46(4):577-585.
22. Clifford L, Jia Q, Subramanian A, Yadav H, Schroeder DR, Kor DJ. Risk factors and clinical outcomes associated with perioperative transfusion-associated circulatory overload. *Anesthesiology*. 2017;126(3):409-418.
23. Looney MR, Gilliss BM, Matthey MA. Pathophysiology of transfusion-related acute lung injury. *Curr Opin Hematol*. 2010;17(5): 418-423.
24. Wendelbo Ø, Opheim EN, Hervig T, et al. Cytokine profiling and post-transfusion haemoglobin increment in patients with haematological diseases. *Vox Sang*. 2018; 113(7):657-668.
25. Spitalnik SL, Triulzi D, Devine DV, et al; State of the Science in Transfusion Medicine Working Groups. 2015 Proceedings of the National Heart, Lung, and Blood Institute's State of the Science in Transfusion Medicine symposium. *Transfusion*. 2015;55(9): 2282-2290.
26. Wiesen AR, Hospenthal DR, Byrd JC, Glass KL, Howard RS, Diehl LF. Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding. *Ann Intern Med*. 1994;121(4):278-280.
27. Franchini M, Lippi G. Relative risks of thrombosis and bleeding in different ABO blood groups. *Semin Thromb Hemost*. 2016;42(2): 112-117.
28. Zheng B. Summarizing the goodness of fit of generalized linear models for longitudinal data. *Stat Med*. 2000;19(10):1265-1275.
29. Francis RO, Mahajan S, Rapido F, et al. Reexamination of the chromium-51-labeled posttransfusion red blood cell recovery method. *Transfusion*. 2019;59(7):2264-2275.
30. Donnenberg AD, Kanas T, Triulzi DJ, Dennis CJ, Meyer EM, Gladwin M. Improved quantitative detection of biotin-labeled red blood cells by flow cytometry. *Transfusion*. 2019; 59(8):2691-2698.
31. Edgren G, Ullum H, Rostgaard K, et al. Association of donor age and sex with survival of patients receiving transfusions. *JAMA Intern Med*. 2017;177(6):854-860.
32. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. *Blood*. 2004;104(8):2263-2268.
33. Ferrucci L, Semba RD, Guralnik JM, et al. Proinflammatory state, hepcidin, and anemia in older persons. *Blood*. 2010;115(18): 3810-3816.
34. Salive ME, Cornoni-Huntley J, Guralnik JM, et al. Anemia and hemoglobin levels in older persons: relationship with age, gender, and health status. *J Am Geriatr Soc*. 1992;40(5): 489-496.
35. Cable RG, Glynn SA, Kiss JE, et al; NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II). Iron deficiency in blood donors: the REDS-II Donor Iron Status Evaluation (RISE) study. *Transfusion*. 2012;52(4):702-711.
36. Bandyopadhyay S, Brittenham GM, Francis RO, Zimring JC, Hod EA, Spitalnik SL. Iron-deficient erythropoiesis in blood donors and red blood cell recovery after transfusion: initial studies with a mouse model. *Blood Transfus*. 2017;15(2):158-164.
37. Picker SM, Radojska SM, Gathof BS. Prospective evaluation of double RBC collection using three different apheresis systems. *Transfus Apheresis Sci*. 2006;35(3): 197-205.
38. Picker SM, Radojska SM, Gathof BS. In vitro quality of red blood cells (RBCs) collected by multicomponent apheresis compared to manually collected RBCs during 49 days of storage. *Transfusion*. 2007;47(4):687-696.
39. Acker JP, Hansen AL, Kurach JD, Turner TR, Croteau I, Jenkins C. A quality monitoring program for red blood cell components: in vitro quality indicators before and after implementation of semiautomated processing. *Transfusion*. 2014;54(10):2534-2543.
40. Ran Q, Hao P, Xiao Y, Zhao J, Ye X, Li Z. Effect of irradiation and/or leucocyte filtration on RBC storage lesions. *PLoS One*. 2011;6(3): e18328.
41. Moroff G, Holme S, AuBuchon JP, Heaton WA, Sweeney JD, Friedman LI. Viability and in vitro properties of AS-1 red cells after gamma irradiation. *Transfusion*. 1999;39(2): 128-134.
42. Davey RJ, McCoy NC, Yu M, Sullivan JA, Spiegel DM, Leitman SF. The effect of pre-storage irradiation on posttransfusion red cell survival. *Transfusion*. 1992;32(6):525-528.
43. de Korte D, Thibault L, Handke W, et al; Biomedical Excellence for Safer Transfusion (BEST) collaborative. Timing of gamma irradiation and blood donor sex influences in vitro characteristics of red blood cells. *Transfusion*. 2018;58(4):917-926.
44. Steiner ME, Ness PM, Assmann SF, et al. Effects of red-cell storage duration on patients undergoing cardiac surgery. *N Engl J Med*. 2015;372(15):1419-1429.
45. Lacroix J, Hébert PC, Fergusson DA, et al; Canadian Critical Care Trials Group. Age of transfused blood in critically ill adults. *N Engl J Med*. 2015;372(15):1410-1418.
46. Fergusson DA, Hébert P, Hogan DL, et al. Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial. *JAMA*. 2012;308(14):1443-1451.
47. Heddle NM, Cook RJ, Arnold DM, et al. Effect of short-term vs. long-term blood storage on mortality after transfusion. *N Engl J Med*. 2016;375(20):1937-1945.
48. Dhabangi A, Ainomugisha B, Cserti-Gazdewich C, et al. Effect of transfusion of red blood cells with longer vs shorter storage duration on elevated blood lactate levels in children with severe anemia: the TOTAL

- Randomized Clinical Trial. *JAMA*. 2015; 314(23):2514-2523.
49. Hunsicker O, Hessler K, Krannich A, et al. Duration of storage influences the hemoglobin rising effect of red blood cells in patients undergoing major abdominal surgery. *Transfusion*. 2018;58(8):1870-1880.
50. Cook RJ, Heddle NM, Lee KA, et al. Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial. *Lancet Haematol*. 2017;4(11): e544-e552.
51. Rydén J, Clements M, Hellström-Lindberg E, Höglund P, Edgren G. A longer duration of red blood cell storage is associated with a lower hemoglobin increase after blood transfusion: a cohort study. *Transfusion*. 2019;59(6): 1945-1952.
52. Halmin M, Rostgaard K, Lee BK, et al. Length of storage of red blood cells and patient survival after blood transfusion: a binational cohort study. *Ann Intern Med*. 2017;166(4): 248-256.
53. Sørensen E, Rigas AS, Didriksen M, et al. Genetic factors influencing hemoglobin levels in 15,567 blood donors: results from the Danish Blood Donor Study. *Transfusion*. 2019; 59(1):226-231.
54. Sagiv E, Fasano RM, Luban NLC, et al. Glucose-6-phosphate-dehydrogenase deficient red blood cell units are associated with decreased posttransfusion red blood cell survival in children with sickle cell disease. *Am J Hematol*. 2018;93(5):630-634.
55. Page G, Kanas T, Guo YG, et al. GWAS of osmotic hemolysis in 12,352 healthy blood donors identifies red cell genetic variants associated with steady state hemolysis in patients with sickle cell disease [abstract]. *Blood*. 2017;130(suppl 1). Abstract 1117.
56. Lanteri MC, Kanas T, Keating S, et al; NHLBI Recipient Epidemiology Donor Evaluation Study (REDS)-III Program. Intradonor reproductibility and changes in hemolytic variables during red blood cell storage: results of recall phase of the REDS-III RBC-Omics study. *Transfusion*. 2019;59(1):79-88.
57. Kanas T, Busch MP; National Heart, Lung, and Blood Institute Recipient Epidemiology Donor Evaluation Study III (REDS-III) Programme. Diversity in a blood bag: application of omics technologies to inform precision transfusion medicine. *Blood Transfus*. 2019;1-5.
58. Guo Y, Busch MP, Seielstad M, et al; National Heart, Lung, and Blood Institute Recipient Epidemiology Donor Evaluation Study (REDS)-III. Development and evaluation of a transfusion medicine genome wide genotyping array. *Transfusion*. 2019;59(1):101-111.
59. Elzik ME, Dirschl DR, Dahners LE. Correlation of transfusion volume to change in hematocrit. *Am J Hematol*. 2006;81(2):145-146.
60. Davies P, Robertson S, Hegde S, Greenwood R, Massey E, Davis P. Calculating the required transfusion volume in children. *Transfusion*. 2007;47(2):212-216.
61. Pieracci FM, Barnett CC Jr, Townsend N, et al. Sexual dimorphism in hematocrit response following red blood cell transfusion of critically ill surgical patients. *ISRN Hematol*. 2012;2012: 298345.
62. Lee JH, Kim DH, Kim K, et al. Predicting change of hemoglobin after transfusion in hemodynamically stable anemic patients in emergency department. *J Trauma*. 2010; 68(2):337-341.
63. Naidech AM, Kahn MJ, Soong W, Green D, Batjer HH, Bleck TP. Packed red blood cell transfusion causes greater hemoglobin rise at a lower starting hemoglobin in patients with subarachnoid hemorrhage. *Neurocrit Care*. 2008;9(2):198-203.
64. Otto JM, Plumb JOM, Clissold E, et al. Hemoglobin concentration, total hemoglobin mass and plasma volume in patients: implications for anemia. *Haematologica*. 2017; 102(9):1477-1485.
65. D'Alessandro A, Culp-Hill R, Reisz JA, et al; Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Heterogeneity of blood processing and storage additives in different centers impacts stored red blood cell metabolism as much as storage time: lessons from REDS-III-Omics. *Transfusion*. 2019;59(1): 89-100.
66. DeSimone RA, Hayden JA, Mazur CA, et al. Red blood cells donated by smokers: a pilot investigation of recipient transfusion outcomes. *Transfusion*. 2019;59(8):2537-2543.
67. Vostal JG, Buehler PW, Gelderman MP, et al. Proceedings of the Food and Drug Administration's public workshop on new red blood cell product regulatory science 2016. *Transfusion*. 2018;58(1):255-266.
68. Kanas T, Stone M, Page GP, et al; NHLBI Recipient Epidemiology Donor Evaluation Study (REDS)-III Program. Frequent blood donations alter susceptibility of red blood cells to storage- and stress-induced hemolysis. *Transfusion*. 2019;59(1):67-78.
69. Roubinian NH, Murphy EL, Swain BE, et al; Northern California Kaiser Permanente DOR Systems Research Initiative. Predicting red blood cell transfusion in hospitalized patients: role of hemoglobin level, comorbidities, and illness severity. *BMC Health Serv Res*. 2014; 14(1):213.
70. Carson JL, Guyatt G, Heddle NM, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. *JAMA*. 2016;316(19):2025-2035.
71. Carson JL, Stanworth SJ, Roubinian N, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. *Cochrane Database Syst Rev*. 2016;10: CD002042.